Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data - Summary - MDSpire

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • By

  • Igor Snast

  • Yuliya Valdman-Grinshpoun

  • Naji Bathish

  • Hagit Matz

  • Yuri Shclar

  • Sari Murad

  • Tali Czarnowicki

  • Eran Shavit

  • Liuqing Yang

  • Sandra Goss

  • Inbal Piller Maor

  • Assaf Halperin

  • Shiran Naftalberg Blonder

  • Raanan Cohen

  • Alex Bleterman

  • Moran Barak

  • Lev Pavlovsky

  • March 31, 2026

  • 0 min

Share

Objective:

To evaluate the effectiveness of risankizumab on quality of life, symptom burden, and work productivity in patients with moderate-to-severe psoriasis, and to assess the feasibility of nocturnal scratch monitoring.

Key Findings:
  • 58% of patients achieved DLQI 0/1 after 52 weeks.
  • 81% reported low pruritus (PNRS 0–3).
  • 77% reached sPGA 0/1.
  • Significant improvements in sleep, symptoms, work productivity, and activity impairment were observed.
  • Nocturnal scratch duration was significantly reduced in the digital monitoring subgroup.
Interpretation:

Risankizumab leads to substantial and durable improvements in quality of life, itch severity, and work/activity impairment in patients with moderate-to-severe psoriasis.

Limitations:
  • The study was conducted in a single country (Israel), which may limit generalizability.
  • As a non-interventional study, it may be subject to biases inherent in observational research.
Conclusion:

Risankizumab is effective in improving multiple domains of health-related quality of life in psoriasis patients, and integrating digital monitoring may enhance management strategies.

Original Source(s)

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • by Igor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, Hagit Matz, Yuri Shclar, Sari Murad, Tali Czarnowicki, Eran Shavit, Liuqing Yang, Sandra Goss, Inbal Piller Maor, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Lev Pavlovsky

  • March 31, 2026

Related Content

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial